共 50 条
- [31] Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohortINVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 538 - 546Tachibana, Yusuke论文数: 0 引用数: 0 h-index: 0机构: Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Tamiya, Motohiro论文数: 0 引用数: 0 h-index: 0机构: Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Osaka, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanNegi, Yoshiki论文数: 0 引用数: 0 h-index: 0机构: Hyogo Med Univ, Sch Med, Dept Resp Med & Hematol, Nishinomiya, Hyogo, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Shiotsu, Shinsuke论文数: 0 引用数: 0 h-index: 0机构: Japanese Red Cross Kyoto Daiichi Hosp, Dept Resp Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanTanimura, Keiko论文数: 0 引用数: 0 h-index: 0机构: Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanTakeda, Takayuki论文数: 0 引用数: 0 h-index: 0机构: Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanOkada, Asuka论文数: 0 引用数: 0 h-index: 0机构: Saiseikai Suita Hosp, Dept Resp Med, Suita, Osaka, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanHarada, Taishi论文数: 0 引用数: 0 h-index: 0机构: Fukuchiyama City Hosp, Dept Med Oncol, Fukuchiyama, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanDate, Koji论文数: 0 引用数: 0 h-index: 0机构: Kyoto Chubu Med Ctr, Dept Pulm Med, Nantan, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanChihara, Yusuke论文数: 0 引用数: 0 h-index: 0机构: Uji Tokushukai Med Ctr, Dept Resp Med, Uji, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanHasegawa, Isao论文数: 0 引用数: 0 h-index: 0机构: Saiseikai Shigaken Hosp, Dept Resp Med, Ritto, Shiga, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanTamiya, Nobuyo论文数: 0 引用数: 0 h-index: 0机构: Rakuwakai Otowa Hosp, Dept Resp Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanKatayama, Yuki论文数: 0 引用数: 0 h-index: 0机构: Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanNishioka, Naoya论文数: 0 引用数: 0 h-index: 0机构: Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan论文数: 引用数: h-index:机构:Tokuda, Shinsaku论文数: 0 引用数: 0 h-index: 0机构: Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanKijima, Takashi论文数: 0 引用数: 0 h-index: 0机构: Hyogo Med Univ, Sch Med, Dept Resp Med & Hematol, Nishinomiya, Hyogo, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, JapanTakayama, Koichi论文数: 0 引用数: 0 h-index: 0机构: Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Kyoto, Japan
- [32] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumabTHORACIC CANCER, 2021, 12 (03) : 304 - 313Yamaguchi, Ou论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanKaira, Kyoichi论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanShinomiya, Shun论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanMouri, Atsuto论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanHashimoto, Kosuke论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanShiono, Ayako论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanMiura, Yu论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanAkagami, Tomoe论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanImai, Hisao论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanKobayashi, Kunihiko论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, JapanKagamu, Hiroshi论文数: 0 引用数: 0 h-index: 0机构: Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan
- [33] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainCOST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)Isla, Dolores论文数: 0 引用数: 0 h-index: 0机构: Hosp Clin Univ Lozano Blesa, Zaragoza, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainLopez-Brea, Marta论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ Marques Valdecilla, Santander, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainEspinosa, Maria论文数: 0 引用数: 0 h-index: 0机构: Hosp Reg Univ Malaga, Malaga, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainArrabal, Natalia论文数: 0 引用数: 0 h-index: 0机构: Roche Farma SA, Madrid, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainPerez-Parente, Diego论文数: 0 引用数: 0 h-index: 0机构: Roche Farma SA, Madrid, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainCarcedo, David论文数: 0 引用数: 0 h-index: 0机构: Hygeia Consulting, Madrid, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, SpainBernabe-Caro, Reyes论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ Virgen Rocio, Seville, Spain Univ Seville, Seville, Spain Hosp Clin Univ Lozano Blesa, Zaragoza, Spain
- [34] Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort studyFRONTIERS IN PHARMACOLOGY, 2024, 15Chen, Siyuan论文数: 0 引用数: 0 h-index: 0机构: Med Sch Chinese PLA, Beijing, Peoples R China Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaLi, Tao论文数: 0 引用数: 0 h-index: 0机构: Med Sch Chinese PLA, Beijing, Peoples R China Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaYang, Wenyu论文数: 0 引用数: 0 h-index: 0机构: Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China Nankai Univ, Sch Med, Tianjin, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaWang, Ting论文数: 0 引用数: 0 h-index: 0机构: Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China Nankai Univ, Sch Med, Tianjin, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaQin, Yuhui论文数: 0 引用数: 0 h-index: 0机构: Med Sch Chinese PLA, Beijing, Peoples R China Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaDu, Zhijuan论文数: 0 引用数: 0 h-index: 0机构: Med Sch Chinese PLA, Beijing, Peoples R ChinaLi, Yanan论文数: 0 引用数: 0 h-index: 0机构: Peoples Liberat Army Gen Hosp, Dept Med Oncol, Med Ctr 3, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaCui, Pengfei论文数: 0 引用数: 0 h-index: 0机构: Peoples Liberat Army Gen Hosp, Dept Med Oncol, Senior Dept Oncol, Med Ctr 5, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaHu, Yi论文数: 0 引用数: 0 h-index: 0机构: Peoples Liberat Army Gen Hosp, Dept Med Oncol, Senior Dept Oncol, Med Ctr 5, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R ChinaLiu, Zhefeng论文数: 0 引用数: 0 h-index: 0机构: Peoples Liberat Army Gen Hosp, Dept Med Oncol, Senior Dept Oncol, Med Ctr 5, Beijing, Peoples R China Med Sch Chinese PLA, Beijing, Peoples R China
- [35] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainCost Effectiveness and Resource Allocation, 21Dolores Isla论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,Marta Lopez-Brea论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,María Espinosa论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,Natalia Arrabal论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,Diego Pérez-Parente论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,David Carcedo论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,Reyes Bernabé-Caro论文数: 0 引用数: 0 h-index: 0机构: Hospital Clínico Universitario Lozano Blesa,
- [36] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 studyCANCER, 2023, 129 (01) : 118 - 129Gumus, Mahmut论文数: 0 引用数: 0 h-index: 0机构: Istanbul Medeniyet Univ, Fac Med, Istanbul, Turkey Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyChen, Chieh-, I论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyIvanescu, Cristina论文数: 0 引用数: 0 h-index: 0机构: IQVIA, Amsterdam, Netherlands Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyKilickap, Saadettin论文数: 0 引用数: 0 h-index: 0机构: Istinye Univ, Dept Med Oncol, Fac Med, Liv Hosp, Ankara, Turkey Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyBondarenko, Igor论文数: 0 引用数: 0 h-index: 0机构: Dnipropetrovsk State Med Acad, City Multifield Clin Hosp, Dnepropetrovsk, Ukraine Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyOzguroglu, Mustafa论文数: 0 引用数: 0 h-index: 0机构: Istanbul Univ Cerrahpa, Cerrahpa Med Fac, Istanbul, Turkey Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyGogishvili, Miranda论文数: 0 引用数: 0 h-index: 0机构: High Technol Med Ctr, Tbilisi, Georgia Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyTurk, Haci M.论文数: 0 引用数: 0 h-index: 0机构: Bezmialem Vakif Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyCicin, Irfan论文数: 0 引用数: 0 h-index: 0机构: Trakya Univ, Dept Med Oncol, Iskender Edirne Merkez E, Turkey Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyHarnett, James论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyMastey, Vera论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyNaumann, Ulrike论文数: 0 引用数: 0 h-index: 0机构: IQVIA, Reading, Berks, England Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyReaney, Matthew论文数: 0 引用数: 0 h-index: 0机构: IQVIA, Reading, Berks, England Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyKonidaris, Gerasimos论文数: 0 引用数: 0 h-index: 0机构: Sanofi, Reading, Berks, England Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeySasane, Medha论文数: 0 引用数: 0 h-index: 0机构: Sanofi, Bridgewater, NJ USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyBrady, Keri J. S.论文数: 0 引用数: 0 h-index: 0机构: Sanofi, Cambridge, MA USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyLi, Siyu论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyGullo, Giuseppe论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, TurkeyRietschel, Petra论文数: 0 引用数: 0 h-index: 0机构: Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA Istanbul Medeniyet Univ, Fac Med, Istanbul, Turkey论文数: 引用数: h-index:机构:
- [37] A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)FRONTIERS IN ONCOLOGY, 2024, 14Cafaro, Alessandro论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyFoca, Flavia论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Unit Biostat & Clin Trials, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyNanni, Oriana论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Unit Biostat & Clin Trials, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyChiumente, Marco论文数: 0 引用数: 0 h-index: 0机构: Soc Italiana Farm Clin & Terapia SIFaCT, Sci Direct, Turin, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyCoppola, Marina论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Oncol Veneto IOV, Pharm Unit, Padua, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyBaldo, Paolo论文数: 0 引用数: 0 h-index: 0机构: NCI, Pharm Unit, CRO Aviano IRCCS, Aviano, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyOrzetti, Sabrina论文数: 0 引用数: 0 h-index: 0机构: NCI, Pharm Unit, CRO Aviano IRCCS, Aviano, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyEnrico, Fiorenza论文数: 0 引用数: 0 h-index: 0机构: Hosp Pharm, Candiolo Canc Inst, FPO IRCCS, Turin, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyLadisa, Vito论文数: 0 引用数: 0 h-index: 0机构: Hosp Pharm, IRCCS Natl Canc Inst Fdn, Milan, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyLerose, Rosa论文数: 0 引用数: 0 h-index: 0机构: Hosp Pharm, IRCCS CROB Referral Canc Ctr Basilicata, Rionero In Vulture, PZ, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyNardulli, Patrizia论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Res Ctr, Pharm Unit, Ist Tumori Giovanni Paolo II, Bari, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyMaiolino, Piera论文数: 0 引用数: 0 h-index: 0机构: Ist Nazl Tumori Fdn G Pascale, Pharm Unit, IRCCS, Naples, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyGradellini, Federica论文数: 0 引用数: 0 h-index: 0机构: Pharm Unit, Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyGasbarro, Anna Rita论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Policlin, Pharm Unit, Bari, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyCarrucciu, Gisella论文数: 0 引用数: 0 h-index: 0机构: Pharm Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyProvasi, Riccardo论文数: 0 引用数: 0 h-index: 0机构: Pharm Unit, Azienda Sanit Univ Giuliano Isontina, Trieste, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyCappelletto, Paola Cristina论文数: 0 引用数: 0 h-index: 0机构: Hosp Pharm, Hosp Bolzano SABES ASDAA, Bolzano, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyPasqualini, Alessandra论文数: 0 引用数: 0 h-index: 0机构: Santa Chiara Hosp, Pharm Unit, Trento, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyVecchia, Stefano论文数: 0 引用数: 0 h-index: 0机构: Hosp Guglielmo Saliceto, Pharm Unit, Piacenza, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyVeraldi, Marianna论文数: 0 引用数: 0 h-index: 0机构: Dept Hlth Protect & Hlth Serv Calabria Reg, Protes & Pharmaceut Assistance Sect N 3, Protes & Pharmaceut Assistance Sect N, Catanzaro, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyDe Francesco, Adele Emanuela论文数: 0 引用数: 0 h-index: 0机构: Mater Domini Hosp, Pharm Unit, Catanzaro, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyCrino, Lucio论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Thorac Oncol Unit, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyDelmonte, Angelo论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Thorac Oncol Unit, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, ItalyMasini, Carla论文数: 0 引用数: 0 h-index: 0机构: IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, Italy IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Pharm Unit, Meldola, Italy
- [38] Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort StudyTECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20Zhang, Jie论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaWu, Di论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaZhang, Ziran论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaLong, Jieran论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaTian, Guangming论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaWang, Yang论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaMa, Xiangjuan论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaChen, Xiaoling论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaHan, Jindi论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaHu, Weiheng论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaDai, Ling论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaNie, Jun论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R ChinaFang, Jian论文数: 0 引用数: 0 h-index: 0机构: Peking Univ Canc Hosp & Inst, Beijing, Peoples R China Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
- [39] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabCancer Immunology, Immunotherapy, 2022, 71 : 1747 - 1756Mathilde Bureau论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesThierry Chatellier论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesTanguy Perennec论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesThomas Goronflot论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesCharlotte Greilsamer论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesAnne-Laure Chene论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesRaafet Affi论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesEric Frampas论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesJaafar Bennouna论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de NantesElvire Pons-Tostivint论文数: 0 引用数: 0 h-index: 0机构: University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
- [40] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabCANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756Bureau, Mathilde论文数: 0 引用数: 0 h-index: 0机构: CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceChatellier, Thierry论文数: 0 引用数: 0 h-index: 0机构: Clin Mutualiste Estuaire, Med Oncol Unit, St Nazaire, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FrancePerennec, Tanguy论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Ouest, Dept Radiat Oncol, St Herblain, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceGoronflot, Thomas论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Nantes, Data Clin, INSERM, CIC 1413,PHU 11, Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceGreilsamer, Charlotte论文数: 0 引用数: 0 h-index: 0机构: Hosp La Roche Sur Yon, Med Oncol Unit, La Roche Sur Yon, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceChene, Anne-Laure论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Nantes, Pneumol Unit, Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceAffi, Raafet论文数: 0 引用数: 0 h-index: 0机构: CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceFrampas, Eric论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Nantes, Radiol Unit, Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FranceBennouna, Jaafar论文数: 0 引用数: 0 h-index: 0机构: CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, France CRCINA, INSERM, Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, FrancePons-Tostivint, Elvire论文数: 0 引用数: 0 h-index: 0机构: CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, France CRCINA, INSERM, Nantes, France CHU Nantes, Med Oncol Unit, Univ Hosp Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 Nantes, France